Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) reported Q4 CY2024 results topping the market’s revenue expectations , but sales fell by 4.7% year on year to $707.8 million. On the other hand, the company’s full-year revenue guidance of $2.71 billion at the midpoint came in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.63 per share was 8.5% above analysts’ consensus estimates.
QuidelOrtho (QDEL) Q4 CY2024 Highlights:
Revenue: $707.8 million vs analyst estimates of $698.4 million (4.7% year-on-year decline, 1.4% beat)
Adjusted EPS: $0.63 vs analyst estimates of $0.58 (8.5% beat)
Adjusted EBITDA: $150.3 million vs analyst estimates of $147.3 million (21.2% margin, 2% beat)
Management’s revenue guidance for the upcoming financial year 2025 is $2.71 billion at the midpoint, missing analyst estimates by 2.2% and implying -2.8% growth (vs -6.8% in FY2024)
Adjusted EPS guidance for the upcoming financial year 2025 is $2.32 at the midpoint, missing analyst estimates by 5.3%
EBITDA guidance for the upcoming financial year 2025 is $595 million at the midpoint, above analyst estimates of $589.4 million
Operating Margin: -14.2%, down from 5.4% in the same quarter last year
Constant Currency Revenue fell 4.4% year on year (-14.1% in the same quarter last year)
Market Capitalization: $2.79 billion
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.